Peptide Handling by HLA-B27 Subtypes Influences Their Biological Behavior,Association with Ankylosing Spondylitis and Susceptibility to Endoplasmic Reticulum Aminopeptidase 1 (ERAP1)

HLA-B27 is strongly associated with ankylosing spondylitis (AS). We analyzed the relationship between structure, peptide specificity, folding, and stability of the seven major HLA-B27 subtypes to determine the role of their constitutive peptidomes in the pathogenicity of this molecule. Identification of large numbers of ligands allowed us to define the differences among subtype-bound peptidomes and to elucidate the peptide features associated with AS and molecular stability. The peptides identified only in AS-associated or high thermostability subtypes with identical A and B pockets were longer and had bulkier and more diverse C-terminal residues than those found only among non-AS-associated/lower-thermostability subtypes. Peptides sequenced from all AS-associated subtypes and not from non-AS-associated ones, thus strictly correlating with disease, were very rare. Residue 116 was critical in determining peptide binding, thermodynamic properties, and folding, thus emerging as a key feature that unified HLA-B27 biology. HLA-B27 ligands were better suited to TAP transport than their N-terminal precursors, and AS-associated subtype ligands were better than those from non-AS-associated subtypes, suggesting a particular capacity of AS-associated subtypes to bind epitopes directly produced in the cytosol. Peptides identified only from AS-associated/high-thermostability subtypes showed a higher frequency of ERAP1-resistant N-terminal residues than ligands found only in non-AS-associated/low-thermostability subtypes, reflecting a more pronounced effect of ERAP1 on the former group. Our results reveal the basis for the relationship between peptide specificity and other features of HLA-B27, provide a unified view of HLA-B27 biology and pathogenicity, and suggest a larger influence of ERAP1 polymorphism on AS-associated than non-AS-associated subtypes.The current ideas concerning the pathogenetic role of HLA-B27 in ankylosing spondylitis (AS) emphasize specific antigen presentation (1), misfolding (2), or immunomodulation mediated by heavy chain homodimers (3) expressed at the cell surface upon endosomal recycling (4). Recent research provided evidence that both misfolded HLA-B27 heavy chains and surface expressed B27 homodimers may activate the IL-23/IL-17 axis, a key inflammatory pathway in spondyloarthropathies, through distinct mechanisms, namely the unfolded protein response (5) and the stimulation of IL-17-producing T cells (6). In contrast, the fact that CD8+ T cells are not required for the HLA-B27-associated disease in transgenic rats (7, 8), and the failure to identify specific arthritogenic peptides, point out to a pathogenetic role of HLA-B27 based on its folding and/or non-canonical forms, rather than to an autoimmune mechanism based on molecular mimicry between foreign and self-derived peptides. Yet, on the basis of genetic and immunological studies (9, 10), an involvement of CD8+T cells in the human disease cannot be ruled out.Beyond the pathogenetic relevance of specific peptides, the constitutive HLA-B27-bound peptidome is related to the folding and stability of HLA-B27, because both features are peptide-dependent (11). This is strongly supported by the association of ERAP1, an aminopeptidase that trims peptides to their optimal size for MHC-I binding (12, 13), with ankylosing spondylitis (AS)¹ among HLA-B27-positive individuals (14), and by the demonstration that AS-associated ERAP1 polymorphism has a substantial effect on the HLA-B27 peptidome in live cells (15).Any pathogenetic mechanism must account for the differential association of HLA-B27 subtypes with AS. Whereas B*27:02, B*27:04 and B*27:05 are clearly associated with this disease, B*27:06 and B*27:09 are not (16, 17). B*27:07, a subtype present in multiple populations, is generally associated with AS, with one reported exception (18, 19). All these subtypes have the same structure in the A and B pockets of their peptide binding site, which accommodate the two N-terminal residues of their peptide ligands, but they differ in one or more positions in the F pocket, which binds the C-terminal peptide residue, as well as in other positions of the peptide binding site. In contrast, B*27:03, a subtype prevalent only in populations of Sub-Saharan African ancestry, differs from the B*27:05 prototype by a single Y59H change in the A pocket (20, 21), a difference that also sets it apart from all other subtypes (supplemental Table S1) and affects the binding preferences for N-terminal peptide residues (22–24). The nature of B*27:03 as a putative susceptibility factor for AS is unclear (19). In African populations in which this subtype is prevalent, neither this subtype nor B*27:05 are associated with this disease (25), presumably because of concurrent protective factor(s).In this study we carried out an extensive sequence analysis of HLA-B27 subtype-bound peptidomes to define their differential features as well as the extent and nature of peptide sharing among subtypes. The results revealed the basis for the intimate relationship between peptide specificity, folding, and stability of HLA-B27, provided a unified explanation on how subtype polymorphism alters the molecular biology of HLA-B27 and its association with AS, and demonstrated a differential influence of TAP and ERAP1 on AS-associated and non-AS-associated subtypes.     

The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology?

The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the “usual” BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing Aβ oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed β-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from Aβ neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes.Butyrylcholinesterase (BChE),³ the secondary acetylcholine (ACh)-hydrolyzing enzyme, is associated with the neurofibrillary tangles and amyloid plaques characteristic of Alzheimer disease (AD) (1), which suggests that it functions as a potential AD modulator. BChE activity increases in the AD brain (2–4), where it co-localizes with β-amyloid (Aβ) fibrils (5, 6). Aβ is a 39–42-amino-acid amphiphilic peptide, derived from the transmembrane domain and extracellular region of the Aβ precursor protein (7). At high concentrations, Aβ acquires a β-sheet structure, becomes insoluble, and accumulates in neurotoxic oligomers and fibrils (8) to become the main constituent of plaques in the brain of AD patients. Recent hypotheses attribute causal roles in AD to presenilin (9), oxidative stress (10), metals (11), double hit origin (12), or mitochondrial damage (13). The alternative theories state that Aβ represents a bystander or even a protector rather than the causative factor of disease and that Aβ amyloidogenesis is secondary to other pathogenic events (14). Nevertheless, a wealth of evidence demonstrates a pivotal role for Aβ in the pathogenesis of AD, yielding the amyloid cascade hypothesis (15). According to this hypothesis, the pathological accumulation of Aβ in the brain leads to oxidative stress, neuronal destruction, and finally, the clinical syndrome of AD. It is within this context that we have studied the interactions of the Kalow variant (BChE-K) with Aβ.The C terminus of BChE functions as a tetramerization domain (16, 17) and is responsible for its quaternary organization. Four BChE monomers are held together by the aromatic interactions of seven highly conserved aromatic residues, termed the tryptophan amphiphilic tetramerization domain (WAT) (16, 17). The WAT domain interacts with proline-rich attachment domains, either via proline-rich membrane anchor in brain neurons (18) or, in neuromuscular junctions, with cholinesterase-associated collagen Q (19). In the serum, BChE tetramerization is supported by an analogous 17-mer proline-rich peptide derived from lamellipodin (20).Analyzing the quaternary organization of cholinesterases is a complicated task. To date, all biologically relevant crystal structures of cholinesterases have been truncated forms that lack the C terminus of the protein (21), apart from a more recent study of full-length BChE that yielded crystal packing, which did not allow C-terminal interactions among subunits and lacked electron densities in the C terminus region, indicating structural disorder Protein Data Bank (PDB) code 1VZJ (22). Of note, the crystal structure of the homologous C terminus of tetrameric synaptic acetylcholinesterase (AChE-S) could only be determined based on synthetic peptides derived from the sequence of the AChE-S tail and stabilized with a proline-rich attachment domain (23).In addition to the “usual” (BChE-U) form, BChE has nearly 40 genomic variants. The most common is BChE-K, with allelic frequencies of 0.13–0.21. BChE-K includes a single nucleotide polymorphism at position 1699 (single nucleotide polymorphism data base (dbSNP) ID: rs1803274; alleles, A/G). This leads to an alanine-to-threonine substitution at position 539, 36 residues upstream to the C terminus of BChE (24), within the tetramerization domain that we previously found to attenuate amyloid fibril formation (25).Ample evidence supports the importance of alanine-to-threonine substitutions and their relevance to amyloidogenic processes, protein stability, and quaternary organization (supplemental Table ST1). Point mutations at the dimer interface of light chain immunoglobulins decrease their stability so that the A34T polymorphism in this protein leads to systemic amyloidosis (26). An A25T mutant of the tetrameric human protein Transthyretin (TTR), associated with central nervous system amyloidosis, is prone to aggregation and exhibits drastically reduced tertiary and quaternary structural stabilities (27). The thermodynamic stability profile of the A25T TTR mutant shows that both monomers and tetramers of this variant are highly destabilized. In addition, A25T TTR tetramers dissociate very rapidly (about 1200-fold faster than the dissociation of wild-type TTR), reflecting a high degree of kinetic destabilization of their quaternary structure. These factors together probably contribute to the high propensity of A25T TTR to aggregate in vitro.The capacity of serum BChE-K to hydrolyze butyrylthiocholine was reported to be reduced by 30% relative to BChE-U, for yet unclear reasons (24). The reduced hydrolytic activity of BChE-K predicts that BChE-K carriers would potentially sustain improved cholinergic transmission as compared with BChE-U carriers and has been shown to correlate with preserved performance of attention and reduced rates of cognitive decline (28). However, BChE-K carriers are refractory to cholinesterase inhibitor therapy, the current leading treatment of AD (29). This raised the question whether BChE-K functions as an AD risk or protection factor. Genotype studies are controversial, with some showing increased risk of AD for homozygote BChE-K carriers (e.g. Ref. 30), whereas others suggest a protective effect (e.g. Ref. 31). A recent meta-analysis concluded that on average, BChE-K is neither a risk factor nor a protection factor for AD (32). Based on our previous findings of the arrest of Aβ fibril formation by BChE and considering the accumulation of monomeric BChE in the most severe AD cases (33), we used a variety of chemical techniques to study the effect of the A539T substitution on BChE stability and tetramerization on the one hand and on its potency in attenuating Aβ oligomerization and fibril formation on the other.     

The LAT Story: A Tale of Cooperativity, Coordination, and Choreography

The adapter molecule LAT is a nucleating site for multiprotein signaling complexes that are vital for the function and differentiation of T cells. Extensive investigation of LAT in multiple experimental systems has led to an integrated understanding of the formation, composition, regulation, dynamic movement, and function of LAT-nucleated signaling complexes. This review discusses interactions of signaling molecules that bind directly or indirectly to LAT and the role of cooperativity in stabilizing LAT-nucleated signaling complexes. In addition, it focuses on how imaging studies visualize signaling assemblies as signaling clusters and demonstrate their dynamic nature and cellular fate. Finally, this review explores the function of LAT based on the interpretation of mouse models using various LAT mutants.     

Multiple,Non-conserved,Internal Viral Ligands Naturally Presented by HLA-B27 in Human Respiratory Syncytial Virus-infected Cells

Cytotoxic T lymphocyte (CTL)-mediated death of virus-infected cells requires prior recognition of short viral peptide antigens that are presented by human leukocyte antigen (HLA) class I molecules on the surface of infected cells. The CTL response is critical for the clearance of human respiratory syncytial virus (HRSV) infection. Using mass spectrometry analysis of complex HLA-bound peptide pools isolated from large amounts of HRSV-infected cells, we identified nine naturally processed HLA-B27 ligands. The isolated peptides are derived from six internal, not envelope, proteins of the infective virus. The sequences of most of these ligands are not conserved between different HRSV strains, suggesting a mechanism to explain recurrent infection with virus of different HRSV antigenic subgroups. In addition, these nine ligands represent a significant fraction of the proteome of this virus, which is monitored by the same HLA class I allele. These data have implications for vaccine development as well as for analysis of the CTL response.The recognition of short viral peptides associated with human histocompatibility complex (human leukocyte antigen (HLA)¹) class I molecules on the cell surface allows cytotoxic T lymphocytes (CTLs) to recognize and kill virus-infected cells (1). These peptides are generated by proteolytic processing of newly synthesized viral proteins in the cytosol by the combined action of proteasomes, ERAAP (endoplasmic reticulum aminopeptidase associated with antigen processing), and in some cases other peptidases (2). This degradation of viral proteins generates peptides of 8–11 residues that are translocated to the endoplasmic reticulum lumen by transporters associated with antigen processing. These short peptides then assemble with the HLA class I heavy chain and β₂-microglobulin. Usually, two major anchor residues in the antigenic peptide, at position 2 and the C terminus (3, 4), must be deeply accommodated into specific pockets of the antigen recognition site of the HLA class I molecule to stabilize the nascent complexes (5, 6) and allow for their subsequent transport to the cell membrane where they are exposed for CTL recognition (7).Human respiratory syncytial virus (HRSV) (8), a member of the Paramyxoviridae family, is the single most important cause of bronchiolitis and pneumonia in infants and young children (9–11). Infections of this virus occur in people of all ages, but although usually mild infections are reported in healthy adults, HRSV poses a serious health risk in immunocompromised individuals (12, 13) and in the elderly (14, 15). The single-stranded, negative-sense RNA genome of this enveloped virus codes for 11 proteins.Although the immune mechanism involved in HRSV disease and protection is not well understood, specific CD8⁺ T lymphocytes are required for the clearance of virus-infected cells (16). Previously, several HRSV epitopes restricted by different HLA class I molecules were identified using CTLs from seropositive individuals (17–21). However, these experiments were performed with synthetic peptides against individual proteins. In contrast, only one published study attempted to elucidate the nature and diversity of the possible array of HRSV ligands restricted by individual HLA molecules (22). In this study, virus-infected cells were cultured with stable, isotope-labeled amino acids, which were expected to act as anchor residues for the HLA allele of interest. The MHC molecules were then immunoprecipitated, and mass spectrometry analysis was performed. This study identified one HRSV ligand for each of the HLA-A2 and -B7 class I molecules (22). Therefore, is only one HRSV ligand restricted by a single HLA molecule exposed on the cell membrane surface as suggested by this study? Conversely, could a particular HLA molecule bind several ligands of this small virus simultaneously? To answer these questions, we compared HLA-B27 ligands isolated from large amounts of healthy or HRSV-infected cells without any methodological bias (selection of individual protein, use of HLA consensus scoring algorithms, etc.). This analysis demonstrated the existence of diverse, naturally processed HLA-B27 ligands from six different HRSV proteins in infected cells.     

Expression of endo-1,4-β-glucanase (cel1) in Arabidopsis thaliana is associated with plant growth, xylem development and cell wall thickening

Arabidopsis thaliana CEL1 protein was detected in young expanding tissues. Immunostaining revealed that CEL1 accumulated mostly in xylem cells. The primary, as well as the secondary xylem showed considerable CEL1 staining. CEL1 was also observed in young epidermal cells, in which the thicker lateral and tangential walls stained more intensely than the inner walls. In newly formed cell walls, the lateral tangential walls were labeled more intensively than the inner walls. Cellulase activity was found to be significantly higher in growing tissue compared to mature parts of the plant. Cel1 expression concurrently with cellulase activity could be restored in detached matured leaves by sucrose treatment after 48 h in the culture medium.     

Carbohydrate binding modules: biochemical properties and novel applications.

Polysaccharide-degrading microorganisms express a repertoire of hydrolytic enzymes that act in synergy on plant cell wall and other natural polysaccharides to elicit the degradation of often-recalcitrant substrates. These enzymes, particularly those that hydrolyze cellulose and hemicellulose, have a complex molecular architecture comprising discrete modules which are normally joined by relatively unstructured linker sequences. This structure is typically comprised of a catalytic module and one or more carbohydrate binding modules (CBMs) that bind to the polysaccharide. CBMs, by bringing the biocatalyst into intimate and prolonged association with its substrate, allow and promote catalysis. Based on their properties, CBMs are grouped into 43 families that display substantial variation in substrate specificity, along with other properties that make them a gold mine for biotechnologists who seek natural molecular "Velcro" for diverse and unusual applications. In this article, we review recent progress in the field of CBMs and provide an up-to-date summary of the latest developments in CBM applications.     

A Viral,Transporter Associated with Antigen Processing (TAP)-independent,High Affinity Ligand with Alternative Interactions Endogenously Presented by the Nonclassical Human Leukocyte Antigen E Class I Molecule

The transporter associated with antigen processing (TAP) enables the flow of viral peptides generated in the cytosol by the proteasome and other proteases to the endoplasmic reticulum, where they complex with nascent human leukocyte antigen (HLA) class I. Later, these peptide-HLA class I complexes can be recognized by CD8⁺ lymphocytes. Cancerous cells and infected cells in which TAP is blocked, as well as individuals with unusable TAP complexes, are able to present peptides on HLA class I by generating them through TAP-independent processing pathways. Here, we identify a physiologically processed HLA-E ligand derived from the D8L protein in TAP-deficient vaccinia virus-infected cells. This natural high affinity HLA-E class I ligand uses alternative interactions to the anchor motifs previously described to be presented on nonclassical HLA class I molecules. This octameric peptide was also presented on HLA-Cw1 with similar binding affinity on both classical and nonclassical class I molecules. In addition, this viral peptide inhibits HLA-E-mediated cytolysis by natural killer cells. Comparison between the amino acid sequences of the presenting HLA-E and HLA-Cw1 alleles revealed a shared structural motif in both HLA class molecules, which could be related to their observed similar cross-reactivity affinities. This motif consists of several residues located on the floor of the peptide-binding site. These data expand the role of HLA-E as an antigen-presenting molecule.     

Combinatorial Method for Overexpression of Membrane Proteins in Escherichia coli

Membrane proteins constitute 20–30% of all proteins encoded by the genome of various organisms. Large amounts of purified proteins are required for activity and crystallization attempts. Thus, there is an unmet need for a heterologous membrane protein overexpression system for purification, crystallization, and activity determination. We developed a combinatorial method for overexpressing and purifying membrane proteins using Escherichia coli. This method utilizes short hydrophilic bacterial proteins, YaiN and YbeL, fused to the ends of the membrane proteins to serve as facilitating factors for expression and purification. Fourteen prokaryotic and mammalian membrane proteins were expressed using this system. Moderate to high expression was obtained for most proteins, and detergent solubilization combined with a short purification process produced stable, monodispersed membrane proteins. Five of the mammalian membrane proteins, overexpressed using our system, were reconstituted into liposomes and exhibited transport activity comparable with the native transporters.     

Fn14?Trail Effectively Inhibits Hepatocellular Carcinoma Growth

Background

New strategies for the treatment of hepatocellular carcinoma (HCC) are needed, given that currently available chemotherapeutics are inefficient. Since tumor growth reflects the net balance between pro-proliferative and death signaling, agents shifting the equilibrium toward the latter are of considerable interest. The TWEAK:Fn14 signaling axis promotes tumor cell proliferation and tumor angiogenesis, while TRAIL:TRAIL-receptor (TRAIL-R) interactions selectively induce apoptosis in malignant cells. Fn14•TRAIL, a fusion protein bridging these two pathways, has the potential to inhibit tumor growth, by interfering with TWEAK:Fn14 signaling, while at the same time enforcing TRAIL:TRAIL-R-mediated apoptosis. Consequently, Fn14•TRAIL''s capacity to inhibit HCC growth was tested.

Results

Fn14•TRAIL induced robust apoptosis of multiple HCC cell lines, while sparing non-malignant hepatocyte cell lines. Differential susceptibility to this agent did not correlate with expression levels of TRAIL, TRAIL-R, TWEAK and Fn14 by these lines. Fn14•TRAIL was more potent than soluble TRAIL, soluble Fn14, or a combination of the two. The requirement of both of Fn14•TRAIL''s molecular domains for function was established using blocking antibodies directed against each of them. Subcutaneous injection of Fn14•TRAIL abrogated HCC growth in a xenograft model, and was well tolerated by the mice.

Conclusions

In this study, Fn14•TRAIL, a multifunctional fusion protein originally designed to treat autoimmunity, was shown to inhibit the growth of HCC, both in vitro and in vivo. The demonstration of this fusion protein’s potent anti-tumor activity suggests that simultaneous targeting of two signaling axes by a single fusion can serve as a basis for highly effective anti-cancer therapies.